Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
Thirty-four patients resistant to cyclophosphamide and Adriamycin received hexamethylmelamine at one of two dose regimens: 6 mg/kg/day orally for 21 days every 4 weeks or 8 mg/kg/day orally for 21 days every 6 weeks. Only five patients responded. Tolerance to the drug was, however, satisfactory; nausea, pyrosis, and vomiting were the only frequent side effects. Myelosuppression occurred in only one case.
D000328:Adult; D000368:Aged; D006585:Altretamine / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014227:Triazines / Q000008:administration & dosage*
D014227:Triazines; D004317:Doxorubicin; D003520:Cyclophosphamide; D006585:Altretamine